Topical Area: Obesity, Energy and Macronutrient Metabolism
Results : Growth performance including final body weight, weight gain, and feed intake were not altered by BA. Body fat mass was decreased by all BA treated groups (p< 0.01) without changes of lean mass. Energy expenditure contributed by β-oxidation was increased by BA 25 (p< 0.001). Serum lipid profiles including triglyceride, free fatty acid, total cholesterol, and LDL cholesterol were significantly improved by all BA treated groups (p< 0.001). Lipid accumulation in the liver was reduced by BA 15 and 25 (all p< 0.001). The mRNA expressions of Acc1and Scd1were dose-dependently suppressed by betulinic acid in liver (p< 0.05). Srebp1was diminished by BA treated groups (all p< 0.05). Fasshowed reduced tendency by BA (p=0.06). In protein levels, ACC1 and SCD1 were inhibited by BA treated groups (p< 0.001 and p< 0.05). FAS and SREBP1 tended to be reduced by BA (p=0.40 and p=0.70). LPL and CPT1, β-oxidation markers in skeletal muscle, were activated by BA 25 (p< 0.001 and p< 0.01). The activation of CPT1 was influenced by stimulating of AMPK-pT172 and ACC1-pS79 (all p< 0.05). Taken together, BA inhibitedde novolipogenesis in the liver and upregulated key proteins related to β-oxidation in skeletal muscle, contributing to the prevention of obesity and dyslipidemia.
Funding Sources : National Research Foundation of Korea